Glioblastoma is one of the most malignant forms of cancer, for which no effective targeted therapy has been found. Although The Cancer Genome Atlas has provided a list of fusion genes in glioblastoma, their role in progression of glioblastoma remains largely unknown. To search for novel fusion genes, we obtained RNA-seq data from TGS-01 human glioma-initiating cells, and identified a novel fusion gene (HMGA2-EGFR), encoding a protein comprising the N-terminal region of the highmobility group AT-hook protein 2 (HMGA2) fused to the C-terminal region of epidermal growth factor receptor (EGFR), which retained the transmembrane and kinase domains of the EGFR. This fusion gene product showed transforming potential and a high tumor-forming capacity in cell culture and in vivo. Mechanistically, HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B than EGFRvIII, an in-frame exon deletion product of the EGFR gene that is commonly found in primary glioblastoma. Forced expression of HMGA2-EGFR enhanced orthotopic tumor formation of the U87MG human glioma cell line. Furthermore, the EGFR kinase inhibitor erlotinib blocked sphere formation of TGS-01 cells in culture and inhibited tumor formation in vivo. These findings suggest that, in addition to gene amplification and in-frame exon deletion, EGFR signaling can also be activated by gene fusion, suggesting a possible avenue for treatment of glioblastoma.
of EGFR activation in glioblastoma. 5 For example, the most frequent functional gene fusion, EGFR-SEPT14, which occurs in 3% of human glioblastoma, confers constitutively active signal transducer and activator of transcription 3 (STAT3) signaling, mitogen independence, and sensitivity to EGFR kinase inhibition. 11 High-mobility group AT-hook protein 2 (HMGA2) is an architectural transcription factor, which modulates gene expression by remodeling the chromatin state. Rearrangements of HMGA2 have been detected in human mesenchymal tumors, lipomas, pleomorphic adenomas, gastrointestinal tumors, osteosarcomas and uterine leiomyomas. 12 In the case of brain tumors, the expression levels of HMGA2 are significantly higher in glioblastoma multiforme and anaplastic astrocytoma than in diffuse astrocytoma. 13 However, no oncogenic fusion genes containing HMGA2 have yet been characterized in glioblastoma.
In our study, we have identified a novel fusion gene involving HMGA2 and EGFR from a human glioblastoma specimen. The protein product of HMGA2-EGFR exhibited tumor-forming capacity in cell culture and in vivo. Importantly, an EGFR inhibitor, erlotinib, inhibited the growth of glioblastoma cells expressing this fusion gene in an orthotropic glioblastoma mouse model and prolonged survival of mice.
Material and Methods

Patient samples
Use of patient-derived glioblastoma tissues and gliomainitiating cells (GICs) was approved by the research ethics committee of the Graduate School of Medicine, the University of Tokyo.
Cell culture
TGS-01, TGS-02, TGS-04 and TGS-05 cells were derived from tumors obtained during surgery from patients (ages from 54 to 68, male cases) with grade IV glioblastomas as described previously.
14 Briefly, tumor was minced by surgical blades in the PBS supplemented with 0.63% glucose and 53 penicillin/streptomycin. A 70-lm cell strainer was used to remove large tissue and the cells were centrifuged, resuspended in the sphere culture medium (Dulbecco's modified Eagle's medium (DMEM)/F12 serum-free medium (Thermo Fisher Scientific, Waltham, MA) supplemented with B27
(Thermo Fisher Scientific), 20 ng/ml EGF and 20 ng/ml basic fibroblast growth factor (both from Pepro Tech, Rocky Hill, NJ)), and cultured at 378C with 5% CO 2 using Ultra-Low attachment cell culture flask (#3814, Corning, Corning, NY). Thereafter, these cell lines were maintained as sphere cultures. U87MG cells were obtained from Dr. Webster Cavenee (Ludwig Institute for Cancer Research, San Diego). U87MG cells were maintained in DMEM supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 lg/ml streptomycin (Thermo Fisher Scientific) and were authenticated by STR profiling. U87MG cell lines stably expressing green fluorescent protein (GFP), ZsGreen, wild-type EGFR, EGFRvIII and HMGA2-EGFR were generated using lentiviral expression vectors obtained from Dr. Hiroyuki Miyoshi (RIKEN BioResource Center; present address: Keio University, Tokyo, Japan).
Antibodies and reagents
Antibodies and kinase inhibitors were used as follows: For in situ proximity ligation assay (PLA): anti-HMGA2 (#ab97276, Abcam, Cambridge, MA) and anti-EGFR (#05-1047, Millipore, Billerica, MA); flow cytometry: anti-HMGA2 (#ab97276, Abcam); immunoblotting: anti-EGFR (#04-338, Millipore), anti-EGFR (pY845) (#ab97613, Abcam), anti-HMGA2 (#ab97276, Abcam), anti-a-tubulin (#T6199, SigmaAldrich, St. Louis, MO), anti-ERK1/2 (#05-1152, Millipore), anti-pERK (#9101, Cell Signaling Technology, Danvers, MA), anti-phospho-signal transducer and activator of transcription 5B (STAT5B) pY694 (#611964, BD Biosciences, Franklin Lakes, NJ), anti-STAT5 (#9310, Cell Signaling Technology), anti-phospho-STAT3 (#9134, Cell Signaling Technology), anti-STAT3 (#9139, Cell Signaling Technology), anti-HDAC1 (#2E-10, Upstate, Billerica, MA), anti-Src (#ab109381, Abcam), anti-phospho-Src (#2101, Cell Signaling Technology), anti-Janus kinase 2 (anti-Jak2; #ab108596, Abcam), anti-phospho-Jak2 (#ab32101, Abcam), anti-b-actin (AC15, #A5441, Sigma-Aldrich), anti-B-cell lymphoma-extra large (anti-Bcl-XL; #2764, Cell Signaling Technology), anti-cyclin D1 (#sc-20044, Santa Cruz Biotechnology, Dallas, TX) and anti-Aurora kinase A (anti-Aurora-A; #17132, Transduction Lab, Lexington, KY); Erlotinib was purchased from Cayman Chemical (Ann Arbor, MI). PP2 was from Abcam (#ab120308) and dasatinib (#9052) was from Cell Signaling What's new? Fusion genes are promising targets for the development of novel drug therapies against glioblastoma. Little is known, however, about their role in the disease. Here, a novel fusion gene, HMGA2-EGFR, was identified from a human glioblastoma specimen containing glioma-initiating cells (GICs). Forced expression of the HMGA2-EGFR fusion protein induced transformation of NIH3T3 fibroblasts and, in glioblastoma cells, induced STAT5B phosphorylation, similar to the known EGFR mutant EGFRvIII. HMGA2-EGFR overexpression also accelerated the growth of orthotopic U87MG tumors in mice, while the EGFR inhibitor erlotinib suppressed tumor formation by HMGA2-EGFR-expressing GICs and prolonged the survival of tumor-bearing mice.
Technology. WP-1066 (#573097), Jak inhibitor I (#420099) and SD-1029 (#573098) were from Millipore. siRNAs against HMGA2-EGFR were designed targeting the fusion-junction of the transcript as follows; si1: sense,
0 (RNAi Inc., Tokyo, Japan). A predesigned control siRNA (siC, #Banno-nega-con, sequence not available) was obtained from RNAi Inc.
Expression plasmids
The HMGA2-EGFR expression plasmid was generated by polymerase chain reaction (PCR) using TGS-01 cDNA as the template and confirmed by sequencing. A kinase inactive mutant (K254M) of HMGA2-EGFR was constructed by sitedirected mutagenesis. Expression plasmids for the wild-type and K254M mutant of the HMGA2-EGFR fusion were HA epitope tagged at their C-termini and subcloned into the pcDNA3 vector and pMXS 15 
Transformation assay
The transforming activity of HMGA2-EGFR was evaluated as described previously. 15 pMXS-based expression plasmids were used to generate recombinant ecotropic retroviruses, which were then used to infect mouse NIH3T3 fibroblasts. The formation of transformed foci was evaluated after culturing the cells for 9 days. The assay was repeated with essentially the same results. The same set of 3T3 cells was injected subcutaneously into nu/nu mice, and tumor formation was examined after 15 days.
Confocal fluorescence microscopy
HEK293T cells were seeded into six-well culture slides (BD Biosciences) coated with 30 lg/ml collagen type I-C (Nitta Gelatin, Osaka, Japan). Twenty-four hours after transfection, cells were fixed with 4% paraformaldehyde and washed three times with PBS. For detection of FLAG-HMGA2-EGFR, cells were incubated with anti-FLAG antibody in Blocking One (Nacalai Tesque, Kyoto, Japan) overnight at 48C. Then, the cells were incubated with secondary antibodies for 1 hr at room temperature. Fluorescence was detected by confocal laser scanning microscopy (LSM-510 META, Carl Zeiss, Jena, Germany).
Flow cytometry
Cells were dissociated into single-cell suspensions and labeled with a phycoerythrin-conjugated HMGA2 antibody. The expression level of cell surface HMGA2 was analyzed using a LSRII flow cytometer (BD Biosciences).
Sphere formation assay
TGS-01 and TGS-04 cells were seeded on the non-tissueculture-treated 96 wells plate (500 cells/well, BD Biosciences) for 7 days. All spheres in each well were counted using a microscope (magnification, 340).
Cell lysis and immunoblotting
Cells were lysed in buffer containing 1% Nonidet P-40, 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM PMSF, 1% aprotinin and 5 mM EDTA. Proteins in cleared cell lysates were resolved by SDS-PAGE and transferred to a Fluoro Trans W membrane (Pall, Port Washington, NY). Immunoblotting was performed using the indicated antibodies.
Fractionation of nuclear and cytoplasmic proteins
Fractionation of nuclear and cytoplasmic proteins from TGS-01 and TGS-04 cells was performed using the NE-PER nuclear and cytoplasmic extraction reagents according to the manufacturer's instructions (Thermo Fisher Scientific).
RNA isolation and RT-PCR analysis
Total RNA from TGS-01 and TGS-04 cells was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany) and reverse transcribed by oligo-dT priming and a PrimeScript II first-strand cDNA synthesis kit (TaKaRa Bio, Osaka, Japan). First-strand cDNA synthesis from the total RNAs of the clinical tumor specimens GB1, GB2, GB3 and GB4 was performed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Note that TGS-01 and TGS-04 cells were isolated from the GB1 and GB2 specimens, respectively. The HMGA2-EGFR fusion cDNA was detected by RT-PCR analysis using primer set 1 (forward 1 (Fwd1):
0 ) were used as a control.
Colony formation assay
Colony formation assay in soft agar was performed as described previously. 17 U87MG cells were seeded at 3,000 cells per well in 0.3% agar and cultured for 2 weeks. Colony size was measured using the cellSens Standard software (version 1.4, OLYMPUS, Tokyo, Japan).
Intracranial xenograft model of glioblastoma
All animal experiments were approved by the animal experiment committee of the Graduate School of Medicine, the University of Tokyo. Viable TGS-01 cells ( female BALB/c nu/nu mice at a depth of 3 mm. Survival of mice was analyzed by Kaplan-Meier plot and log-rank test.
In vivo bioluminescence imaging
In vivo bioluminescence imaging was performed with Berthold Nightowl for data acquisition (Berthold Technologies, Bad Wildbad, Germany), as described previously. 18 Mice were anesthetized and imaged at 6 min after intraperitoneal injection of D-luciferin.
Identification of fusion genes using RNA-seq data RNA-seq data for TGS-01 cells were acquired in our previous study. 19 Raw data are available at the DDBJ Japanese genotype-phenotype archive for genetic and phenotypic human data (JGAS00000000077). The de novo identification of fusion genes was performed using FusionMap. 20 Whole genome sequencing and identification of the chromosomal breakpoint Genomic DNA was purified from TGS-01 cells and a library was made using the Ion Fragment plus library Kit. Highthroughput sequencing of the genomic library was performed using IonProton, Ion PI Template OT2 200 Kit v3, and Ion PI Sequencing 200 Kit v3 (Thermo Fisher Scientific). 21 The break point was determined using the "grep" command-based method, as described previously. 22 The genomic sequence "ATTTGGCTTTCCCCACTCACACACACTAAA," located in the fourteenth intron of the wild-type EGFR gene was used for identification, and nine independent sequence reads, all of which contained the same breakpoint, were identified.
In situ PLA
The HMGA2-EGFR fusion protein was detected in clinical samples by PLA (Duolink, Olink Bioscience, Uppsala, Sweden), according to the manufacturer's instructions. Sections from formalin-fixed, paraffin-embedded glioblastoma samples were rehydrated, subject to antigen retrieval with 10 mM citrate buffer (pH 6.0), and incubated with a mouse anti-EGFR monoclonal antibody (Millipore) and rabbit anti-HMGA2 polyclonal antibody (Abcam), both of which were directly conjugated to the PLA oligonucleotide arm using a conjugation kit (Olink Bioscience). PLA signals were detected with an LSM-510 META confocal microscope (Carl Zeiss). TO-PRO-3 (Thermo Fisher Scientific) staining was used to identify cell nuclei, and approximately 50 individual cell images per sample were quantified. For detection of HMGA2-EGFR in sphere cultures of TGS-01 and TGS-04 cells, PLA oligonucleotide-conjugated secondary antibodies were used instead of PLA oligonucleotide conjugation to the primary antibodies. DAPI (Olink Bioscience) was used for counterstaining, and PLA signals were detected with an AF6000 (Leica Microsystems, Wetzlar, Germany).
Genomic PCR for identification of HMGA2-EGFR
Genomic DNA was extracted from TGS-01 and TGS-04 cells. The following primer pairs were used for PCR: primer set 1:
0 ), and primer set 2 (Fwd1: 5 0 -GTTGAAACCTGATTCCTGCAA-3 0 (the same primer to primer set 1), Rev2: 5 0 -CTGGAGAGAAACGCAAAAGC-3 0 ).
Statistical analysis
The Mann-Whitney U test was used to determine the p-values shown in the figures. The Steel-Dwass method was used for multiple comparisons of the data. One-way repeated measure ANOVA and Dunnett's multiple comparisons test were used for the erlotinib sensitivity test. Accession numbers. Raw whole genome sequencing (WGS) data for TGS-01 cells are available at NBDC (JGAS00000000096).
Results
Identification of the HMGA2-EGFR gene fusion
To find fusion genes in glioblastoma, we used GICs termed TGS-01, obtained from a patient with glioblastoma. The GICs have the ability to self-renew and mimic the original tumor following transplantation into the brain of immunocompromised mice. 14 We analyzed an RNA-seq data from TGS-01 cells using FusionMap. 20 The analysis of the RNAseq data led to the discovery of HMGA2-EGFR fusion as the most abundant chimeric transcript (Fig. 1a , Supporting Information Table S1 ). HMGA2-EGFR fusion mRNA was detected by RT-PCR analysis using two primer sets in TGS-01 cells, but not in TGS-04 cells established from another patient with glioblastoma (Fig. 1b) . 14 Moreover, the fusion transcript was detected by RT-PCR in the original surgical specimen of the TGS-01 cells (GB1), but not in other surgical specimens, including GB2, from which the TGS-04 cells were isolated.
To identify the chromosomal breakpoint, we extracted genomic DNA from TGS-01 cells and performed WGS. Due to the low sequencing depth of these data we could not take a genome-wide approach to identify somatic mutations. We therefore used "grep" to identify the breakpoint as described, 22 which was confirmed for all output sequences.
We then designed primers flanking the breakpoint to amplify genomic DNA (Fig. 1c) . The result of Sanger sequencing of the genomic PCR product verified our WGS data (Fig. 1d) .
Immunoblot analysis revealed the expression of endogenous HMGA2-EGFR protein in TGS-01 cells, but not in TGS-04 cells (Fig. 1e) . Of note, weak expression of wild-type EGFR was also detected, while other known mutations of EGFR were not found in TGS-01 cells from our RNA-seq data. We also examined HMGA2-EGFR fusion protein expression in sphere cultures of TGS-01 cells using in situ PLA, and found the presence of HMGA2 and EGFR antigens in the proximity in TGS-01 cells, compared to TGS-04 cells used as a control (Fig. 1f) . Expression of the HMGA2-EGFR protein in the original surgical specimen of TGS-01 (GB1) was then evaluated by the in situ PLA, due to limited availability of formalin-fixed paraffin-embedded (FFPE) materials. The resulting data indicated the presence of PLA signals in the GB1 specimen (Fig. 1g) .
Transforming activity of the HMGA2-EGFR fusion protein
To examine whether the fusion gene of HMGA2-EGFR has transforming potential, we generated expression plasmids for 
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wild-type HMGA2, wild-type EGFR, HMGA2-EGFR and HMGA2-EGFR (K254M), in which Lys 254 in the ATPbiding site of the kinase domain was replaced with Met. We introduced them into murine NIH3T3 fibroblasts. We also introduced an established fusion gene EML4-ALK as a positive control. Transformed foci were readily identified for cells expressing HMGA2-EGFR and EML4-ALK, but not for those expressing wild-type HMGA2, wild-type EGFR or HMGA2-EGFR (K254M) (Fig. 2a) . Next, we subcutaneously injected the transfected NIH3T3 cells into nude mice, and found that only the NIH3T3 cells expressing HMGA2-EGFR and EML4-ALK formed tumors in mice (Fig. 2b) . These results indicated that HMGA2-EGFR has a transforming ability which depends on its kinase activity.
Effect of HMGA2-EGFR on tumor growth in cell culture and in vivo
To determine the role of HMGA2-EGFR in tumor formation, we established human glioma cell line U87MG with stable expression of ZsGreen, EGFR, EGFRvIII and HMGA2-EGFR, and performed colony formation assay. U87MG cells expressing HMGA2-EGFR as well as EGFRvIII showed significantly enhanced colony formation in soft agar, compared to U87MG cells expressing ZsGreen and wild-type EGFR (Fig.  3a) . Next, to study the effects of HMGA2-EGFR expression in U87MG cells on tumor formation in vivo, we orthotopically implanted U87MG cells expressing GFP, EGFRvIII and HMGA2-EGFR into BALB/c nu/nu mice. We found that tumor growth was accelerated in mice implanted with cells expressing HMGA2-EGFR and EGFRvIII, resulted in diminished survival of mice, compared to mice implanted with control GFP expressing cells (Fig. 3b) .
Functional analysis of HMGA2-EGFR
To study the molecular function of HMGA2-EGFR, we performed immunoblot analysis of several key molecules in the classical EGFR signaling pathway, that is, phosphorylated ERK, STAT3 and STAT5B. U87MG cells expressing HMGA2-EGFR manifested increased amounts of phospho-ERK compared to control cells expressing ZsGreen, and the phospho-ERK amounts are comparable to cells expressing EGFR and EGFRvIII. Levels of phospho-STAT3 were not increased in U87MG cells expressing HMGA2-EGFR compared to controls. We found that the level of phospho-STAT5B was increased in cells expressing HMGA2-EGFR in the absence of EGF stimulation, which is a known effect of EGFRvIII. The constitutive activation of STAT5B was higher in cells expressing HMGA2-EGFR than those expressing EGFRvIII and completely inhibited by an EGFR kinase inhibitor erlotinib (Fig. 4a) . 23 We then performed immunoblot analysis of phosphorylated ERK, STAT3 and STAT5B using a panel of GICs.
14 Only TGS-01 cells expressed HMGA2-EGFR (Fig. 4b) . The amount of phospho-STAT5B was strongly upregulated in TGS-01 cells which express the HMGA2-EGFR protein, compared to other GICs (Fig. 4b) . Next, we examined whether HMGA2-EGFR forms a dimer. HEK293T cells were transiently transfected with FLAG-tagged and HAtagged HMGA2-EGFR and immunoprecipitated with the anti-FLAG antibody. Figure 4c shows that FLAG-tagged HMGA2-EGFR and HA-tagged HMGA2-EGFR were coimmunoprecipitated with the anti-FLAG antibody, indicating that HMGA2-EGFR could form a dimer. Based on these finding, we focused on the phosphorylation of STAT5B induced by HMGA2-EGFR. Latha and colleagues reported that Src kinase inhibitors, but not Jak2 inhibitor, downregulate the phosphorylation of STAT5B induced by EGFRvIII expression in glioma cells. 24 Using a panel of inhibitors, we observed a Src inhibitor PP2 and a BCR-ABL/Src inhibitor dasatinib suppressed the phosphorylation of STAT5B in HMGA2-EGFR expressing U87MG cells (Fig. 4d) . In contrast, both Jak/STAT3 inhibitor WP1066 and pan-Jak inhibitor, Jak inhibitor I, did not show such effects, while Jak2 inhibitor SD-1029 suppressed the phosphorylation of STAT5B. As a control, phosphorylation of HMGA2-EGFR at a tyrosine residue corresponding to Y845 of EGFR, which is known as a target of Src and one of the markers of EGFR activation, 25 was efficiently inhibited by the Src inhibitors.
We also confirmed that phosphorylation of STAT3 was not induced in HMGA2-EGFR expressing cells, and that PP2 and dasatinib showed no effect on the amounts of phospho-STAT3. Although PP2 and dasatinib also inhibited phosphorylation of Jak2 possibly through indirect mechanisms, and PP2 failed to suppress the phosphorylation of Src in our experimental conditions (Fig. 4d) , the effects of PP2 and dasatinib suggested that the phosphorylation of STAT5B was primarily regulated through Src and/or Src family kinases. Since SD-1029 suppressed the phosphorylation of STAT5B, we could not exclude the possibility that Jak kinase also regulates STAT5B phosphorylation in HMGA2-EGFR expressing U87MG cells.
To examine the localization of HMGA2-EGFR, FLAGtagged HMGA2-EGFR was ectopically expressed in HEK293T cells and immunostaining was performed using the anti-FLAG antibody. HMGA2-EGFR was mainly located in the cytosol and plasma membrane (Fig. 5a ). Flow cytometry verified cell surface-expression of HMGA2 in TGS-01 cells, but not in TGS-04 cells, suggesting that HMGA2-EGFR was located at the cell membrane (Fig. 5b) . Importantly, we also examined the localization of endogenous HMGA2-HGFR in TGS-01 cells by fractionation of cytosolic and nuclear proteins, and found that endogenous HMGA2-EGFR was detected in the nucleus as well as in the cytosol (Fig. 5c) .
EGFR is known to translocate to the nucleus and regulate gene expression, for example, cyclin D1. 26 EGFRvIII also translocates to the nucleus to act as a transcription factor to induce Aurora-A and Bcl-XL. 24, 27 The amounts of Aurora-A and Bcl-XL were, however, not increased by forced expression of EGFRvIII and HMGA2-EGFR, possibly because of the constitutive and high amounts of expression of Aurora-A and Bcl-XL in our experimental conditions in U87MG cells (Supporting Information Fig. S1 ).
Inhibition of the malignant phenotype of TGS-01 cells in culture and in vivo by the EGFR inhibitor erlotinib
Based on the observations of enhanced EGFR signaling in HMGA2-EGFR expressing cells, we next studied the effects of the EGFR inhibitor erlotinib on sphere formation using TGS-01 and TGS-04 cells. Erlotinib inhibited proliferation and sphere formation of TGS-01, but not of TGS-04 cells in culture (Fig. 6a) . The effects of erlotinib on the tumorigenic activity of TGS-01 were also assessed in vivo. Treatment with erlotinib inhibited the intracranial growth of TGS-01 cells, and prolonged the survival of mice inoculated with TGS-01 cells (Fig. 6b) . Finally, to confirm the importance of HMGA2-EGFR on sphere formation and STAT5B phosphorylation, we knocked down this fusion gene by designing siRNAs (si1 and si2) at the fusion site of transcript. We confirmed si1 and si2 suppressed the amount of HMGA2-EGFR protein to different extents (Fig. 7a) and found that si2, a more efficient siRNA, downregulated phosphorylation of STAT5B but not STAT3. Sphere-forming ability was consistently downregulated by the siRNAs, although the cells did not show change in the sensitivity to erlotinib, possibly because of the residual fusion protein (Fig. 7b) . These findings suggested the contribution of this fusion protein on the sphere-forming ability of TGS-01 cells.
Discussion
Genetic alterations of the EGFR gene are frequently identified in glioblastoma and have been shown to drive gliomagenesis; 28, 29 however, EGFR inhibitors have shown limited success in terms of the treatment of glioblastoma, implying certain degrees of cellular heterogeneity in glioblastoma. Thus, it is necessary to broaden our understanding of the genetic and signaling variations contributing to glioblastoma development to improve treatment efficacy. In the present study, we identified a novel functional EGFR fusion gene, HMGA2-EGFR, from a glioblastoma patient. Structurally, HMGA2-EGFR comprises the N-terminal region of HMGA2 containing the AT-hook domain and the C-terminal region of EGFR containing the transmembrane and kinase domains. Our observations suggested that this fusion protein contributed to gliomagenesis. First, the fusion protein demonstrated potent transforming activity. Second, similar to the common internal deletion form of EGFR, EGFRvIII, overexpression of HMGA2-EGFR accelerated the growth of orthotopic U87MG tumor in mice. Third, we observed the enhanced activation of several key molecules in the EGFR signaling pathway, including ERK and STAT5B, which appeared to be crucial for the development of glioblastoma, because an EGFR kinase inhibitor, erlotinib, efficiently prevented the growth of HMGA2-EGFR tumors in cell culture and in vivo.
Rearrangements of the HMGA2 gene are frequently identified in human mesenchymal tumors. 30 However, except for the HMGA2-RAD51L1 and HMGA2-LPP fusion genes, all other fusions are out of frame and are predicted to be translated into truncated variants of HMGA2. 12 The HMGA2-EGFR fusion we have identified is a novel in-frame chimeric transcript in glioblastoma. Two other HMGA2 mutants, HMGA2-PTPRR and HMGA2-NUP107, have been reported in glioblastoma by The Cancer Genome Atlas (TCGA); 5 however, biological functions of the HMGA2 fusion genes have not been reported. Investigation of the oncogenic activity of these HMGA2 fusion gene products may highlight a causal role for HMGA2 activity in gliomagenesis. The expression levels of HMGA2 are elevated in hematopoietic and neural stem cells. HMGA2 promotes the self-renewal of neuronal stem cells in fetal and young-adult central nervous systems. 31 Further, the expression levels of HMGA2 correlate with poor prognosis of patients with glioma. 13 Notably, there is an increased expression of HMGA2 in cancer stem cells (CSCs). [32] [33] [34] HMGA2-EGFR comprises the N-terminal region of HMGA2 containing the AT-hook domain. Thus, it may be interesting to assess whether the fusion gene has any impact on CSCs. However, overexpression of HMGA2-EGFR into U87-MG cells did not affect the expression levels of a CSC marker, CD133 (data not shown), suggesting that HMGA2-EGFR primarily influences tumor-forming ability, but not accelerates the expansion of glioma stem cells. EGFRvIII is a truncated extracellular mutant of EGFR commonly found in primary glioblastoma with EGFR amplification, which confers enhanced tumorigenic behavior. In particular, the ERK and STAT5 pathways are highly activated by EGFRvIII. TGS-01 cells expressing the HMGA2-EGFR fusion gene lacked the expression of EGFRvIII (data not shown). We thus determined whether HMGA2-EGFR could provide an alternate way to activate the EGFR pathway. Our data indicate that the HMGA2-EGFR fusion protein primarily acts as a constitutively active form of EGFR. Our data suggested that HMGA2-EGFR overexpression induces STAT5B phosphorylation primarily via Src family kinases as in the case of EGFRvIII, although we could not fully exclude the contribution of Jak2 in the phosphorylation of STAT5B Bioluminescence imaging of orthotopically inoculated TGS-01 cells at 2 weeks after implantation is shown. Representative images of the TGS-01 tumor-bearing nude mice treated with a daily dose of 100 mg/kg erlotinib or control vehicle delivered by oral gavage (left panels). Survival of mice (n 5 8 mice for each condition) was evaluated by Kaplan-Meier analysis (right graph). p-Value was calculated using a log-rank test. (Fig. 4d) . The constitutive STAT5B phosphorylation by HMGA2-EGFR was higher than EGFRvIII in U87MG cells; however, it is possible that the extent of STAT5B activation by each EGFR mutant may differ depending on the cell types and experimental conditions. Activation of STAT5B has reportedly been associated with aggressiveness and increased cell invasion of many types of tumor, including glioblastoma, colorectal cancer and hepatocellular carcinoma, suggesting its important function, downstream of mutant EGFRs. [35] [36] [37] EGFRvIII functions as an activated monomer and alters the signaling cascade for oncogenic transformation, unlike the wild-type EGFR dimer. 38 Our data indicates that HMGA2-EGFR can exist as a dimer and activate EGFR signaling. Fan et al. 39 reported that EGFRvIII localizes to the cell membrane, cytoplasm and nucleus, and that phosphorylation of EGFRvIII mediated by EGFR leads to nuclear translocation of EGFRvIII. We observed that exogenous HMGA2-EGFR is localized predominantly at the cellular membrane in HEK293T cell (Fig. 4c) . In contrast, endogenous HMGA2-EGFR was detected in both the cytosolic and nuclear extracts of TGS-01 cells, raising the possibility that HMGA2-EGFR localization is regulated by certain mechanisms. If the subcellular localization of HMGA2-EGFR influences tumorigenic behavior, manipulation of its localization may influence tumor growth, and this possibility warrants further studies.
EGFRvIII and in-frame gene fusions retaining the tyrosine kinase domain of EGFR in glioblastoma confer sensitivity to EGFR inhibition.
11 EGFR-SEPT14 was identified as a new EGFR activating gene fusion, which was detected in 6 of 185 (3.2%) TCGA samples. 11 The growth of EGFR-SEPT14-positive glioblastoma xenograft tumors was significantly delayed by treatment with the EGFR tyrosine kinase inhibitors, lapatinib and elrotinib. In the present study, we also found that the EGFR inhibitor erlotinib suppressed sphere and tumor formation of TGS-01 cells expressing the HMGA2-EGFR fusion protein, and prolonged survival of mice inoculated with TGS-01 cells orthotopically. Thus, EGFR inhibitors might also provide an effective treatment strategy for patients with glioblastoma with the HMGA2-EGFR and other types of fusion genes with EGFR.
We have found this functional EGFR fusion gene, HMGA2-EGFR, in a single case of glioblastoma and the previous largescale sequencing study in glioblastoma did not identify this mutant. 11 A metaanalysis of fusion transcripts across 13 tumor types also did not identify HMGA2-EGFR. 40 However, considering that gliomas are highly heterogeneous disease, the identification and characterization of the HMGA2-EGFR rearrangement illustrate how common tumorigenic activities can result from a variety of genomic events. In common with the intragenic rearrangements that generate the EGFRvIII allele, we found that the HMGA2-EGFR fusion promotes glioblastoma cell growth, constitutively activates STAT5B signaling, and confers sensitivity to EGFR inhibition. Together with the reported sensitivity of EGFR-SEPT14 expressing glioblastoma cells to EGFR inhibitors, the present findings again highlight the fusion mutations of EGFR as a potential therapeutic target for intervention in glioblastoma.
